These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 38329515)
1. [Advances in the targeted treatment of non-small cell lung cancer]. Ruge L; John F; Scharpenseel H; Wolf J Inn Med (Heidelb); 2024 Mar; 65(3):211-219. PubMed ID: 38329515 [TBL] [Abstract][Full Text] [Related]
2. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer. Chen YM J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257 [TBL] [Abstract][Full Text] [Related]
3. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Gelatti ACZ; Drilon A; Santini FC Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Qi YT; Hou Y; Qi LC Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164 [TBL] [Abstract][Full Text] [Related]
5. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations. Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260 [TBL] [Abstract][Full Text] [Related]
6. Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer. Zhang H Drug Des Devel Ther; 2016; 10():3867-3872. PubMed ID: 27920501 [TBL] [Abstract][Full Text] [Related]
7. Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy. Ghafoor Q; Baijal S; Taniere P; O'Sullivan B; Evans M; Middleton G Pathol Oncol Res; 2018 Oct; 24(4):723-731. PubMed ID: 29270776 [TBL] [Abstract][Full Text] [Related]
8. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). Hsu PC; Jablons DM; Yang CT; You L Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256 [TBL] [Abstract][Full Text] [Related]
12. Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. Yao Y; Yang H; Zhu B; Wang S; Pang J; Wu X; Xu Y; Zhang J; Zhang J; Ou Q; Tian H; Zhao Z Respir Res; 2023 Jan; 24(1):28. PubMed ID: 36698189 [TBL] [Abstract][Full Text] [Related]
13. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596 [TBL] [Abstract][Full Text] [Related]
18. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy. Zhao Y; Wang H; He C J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758 [TBL] [Abstract][Full Text] [Related]
19. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. Juchum M; Günther M; Laufer SA Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435 [TBL] [Abstract][Full Text] [Related]
20. Management and future directions in non-small cell lung cancer with known activating mutations. Gerber DE; Gandhi L; Costa DB Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]